

FORM TR-1 BE PART I

1) Status of the notification

Final

2) Issuer

Name GALAPAGOS
Identification number 0466-460-429

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights
Conclusion or modification of an agreement to act in concert

4) Notification by

A parent undertaking or a controlling person
Persons acting in concert who have concluded an agreement to hold, acquire or dispose of voting securities

5) Persons subject to the notification requirement

Name (& legal form for legal persons)	Address (for legal persons)
Gilead Sciences, Inc.	1209 Orange Street, Wilmington, DE 19801, USA
Galapagos NV	Generaal De Wittelaan L11, bus A3, 2800 Mechelen, Belgium

6) Persons that dispose of, ... voting rights (Only to be filled in if art. 7 of the Law applies)

Name (& legal form for legal persons)	Address (for legal persons)

Please continue entering the information in part II concerning the persons referred to in points 5 and 6

Click

7) Date on which the threshold is crossed

19/01/2016 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

10

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers under point 10

9) Denominator

45.837.043

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
Holder of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Gilead Sciences, Inc.		0		0,00%	
Gilead Biopharmaceutics Ireland Unlimited Company		6.760.701		14,75%	
subtotal		6.760.701		14,75%	
Galapagos NV		0		0,00%	
TOTAL		6.760.701	0	14,75%	0,00%

Start with "groups" of holders. Calculate subtotals and then finish with the persons who are "alone".
The totals, subtotals and % will be updated once you have clicked on <CALCULATE>

B) Equivalent financial instruments	After the transaction					
	Holder of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights
TOTAL			(in relation to all expiration dates)		0	0,00%

The totals will be updated once you have clicked on <CALCULATE>

TOTAL (Voting rights & Equivalent financial instruments)	# of voting rights	% of voting rights
	6.760.701	14,75%

11) Chain of controlled undertakings through which the holding is effectively held, if applicable

Please describe, or join a diagram in attachment

Gilead Biopharmaceutics Ireland Unlimited Company (25/28 North Wall Quay, Dublin 1, D01H104, Ireland) is a direct subsidiary of Gilead Sciences, Inc.
 Gilead Sciences, Inc. has no controlling shareholder.
 Galapagos NV has no controlling shareholder.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again 0 voting rights as of

13) Additional information

A) Convertible bonds and rights to subscribe to voting securities not yet issued					
Holder	Type of financial instrument	Expiration date (DD/MM/YYYY)	Exercise/Conversion period or date	Number	# of voting rights that may be acquired if the instrument is exercised/converted

B) Shares without voting rights	
Holder	Number

C) Remarks

Done at

On (DD/MM/YYYY)

Name & capacity

Signature

Signature



13) Additional information

A) Convertible bonds and rights to subscribe to voting securities not yet issued					
Holder	Type of financial instrument	Expiration date (DD/MM/YYYY)	Exercise/Conversion period or date	Number	# of voting rights that may be acquired if the instrument is exercised/converted

B) Shares without voting rights	
Holder	Number

C) Remarks

Done at

On (DD/MM/YYYY)

Name & capacity

Signature

Signature

